1. Ahn SH, Marcellin P, Ma X, et al. Hepatitis B surface antigen loss with Tenofovir Disoproxil fumarate plus Peginterferon alfa-2a: week 120 analysis. Dig Dis Sci. 2018;63:3487–97.
2. Amin OE, Colbeck EJ, Daffis S, et al. Therapeutic potential of TLR8 agonist GS-9688 (selgantolimod) in chronic hepatitis B: re-modelling of antiviral and regulatory mediators. Hepatology 2020.
3. Arends PSM, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015;64(8):1289–95.
4. Bazinet M, Pantea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated interferon alfa-2a in patients with chronic HBV infection naive to Nucleos(t)ide therapy. Gastroenterology. 2020;158:2180–94.
5. Belloni L, Allweiss L, Guerrieri F, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012;122:529–37.